Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $4.1 million.

  • Day One Biopharmaceuticals' Change in Accured Expenses rose 107.86% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 24.21%. This contributed to the annual value of $42.1 million for FY2024, which is 298.16% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Change in Accured Expenses of $4.1 million as of Q3 2025, which was up 732.45% from $490,000 recorded in Q2 2025.
  • Day One Biopharmaceuticals' Change in Accured Expenses' 5-year high stood at $62.3 million during Q2 2024, with a 5-year trough of -$51.9 million in Q3 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was $1.8 million (2023), whereas its average is $2.8 million.
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Change in Accured Expenses showed a top increase of 3,442.52% in 2024 and a maximum decrease of 4,699.56% in 2024.
  • Over the past 4 years, Day One Biopharmaceuticals' Change in Accured Expenses (Quarterly) stood at $2.1 million in 2022, then surged by 178.00% to $5.9 million in 2023, then spiked by 468.93% to $33.4 million in 2024, then spiked by 107.86% to $4.1 million in 2025.
  • Its Change in Accured Expenses stands at $4.1 million for Q3 2025, versus $490,000 for Q2 2025 and -$27.0 million for Q1 2025.